{
    "clinical_study": {
        "@rank": "95653", 
        "acronym": "KTcesar", 
        "arm_group": [
            {
                "arm_group_label": "Continuous wound infiltration", 
                "arm_group_type": "Experimental", 
                "description": "Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period)."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine wether wound infiltration brings additional\n      analgesia effect after cesarean section with optimal standard postoperative analgesia"
        }, 
        "brief_title": "Additional Effect of Wound Infiltration After Cesarean Section With Optimal Standard Analgesia", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Postoperative Pain", 
            "Anesthesia, Local", 
            "Breast Feeding"
        ], 
        "condition_browse": {
            "mesh_term": "Pain, Postoperative"
        }, 
        "detailed_description": {
            "textblock": "Continuous wound infiltration with local anaesthetic has been shown as a safe and\n      opioid-sparing analgesic method after caesarean section with minimal standard analgesia. We\n      aim to evaluate if this benefit remains when an optimal analgesia is used.\n\n      Primary outcome is morphine consumption. Secondary outcomes is pain scores, maternal\n      recovery including breastfeeding, side effects of morphine, nurse workload and maternal\n      satisfaction.\n\n      Patients scheduled for caesarean delivery will be eligible for the study.\n\n      Patients with emergency caesarean delivery, contraindication to analgesic drugs, hemostasis\n      disorder, ongoing infection, diabetes treated with insulin or chronic opioid use will be\n      excluded from the study.\n\n      One group will receive standard analgesia including celecoxib and intravenous morphine for\n      24 hours with Patient Controlled Analgesia pump. The other group will receive the same\n      standard analgesia with additional levobupivacaine initial bolus followed by a continuous\n      subfascial infiltration of 1.25 mg/ml at 5 ml/h for 48 hours through a multiperforated\n      catheter connected to an elastomeric pump.\n\n      Total morphine consumption, pain and any associated complications will be recorded for 72\n      hours. Women wil be asked to fulfill a questionnaire on the second day after cesarean\n      section, assessing recovery, satisfaction and breastfeeding comfort."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Scheduled cesarean section\n\n        Exclusion Criteria:\n\n          -  Emergency cesarean section\n\n          -  Contraindication to opioids, paracetamol, or local anaesthetic\n\n          -  Ongoing infection\n\n          -  Coagulation disorders\n\n          -  Diabetes treated with insulin\n\n          -  Chronic opioid use"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01751256", 
            "org_study_id": "PoissyStGermainH"
        }, 
        "intervention": {
            "arm_group_label": "Continuous wound infiltration", 
            "description": "Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).", 
            "intervention_name": "Continuous wound infiltration", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Levobupivacaine", 
                "Bupivacaine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Postcesarean Section", 
            "Postoperative Pain", 
            "Care, Postoperative", 
            "Anesthesia, Local", 
            "Breast Feeding", 
            "Morphine", 
            "Pain Measurement", 
            "levobupivacaine"
        ], 
        "lastchanged_date": "December 14, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Poissy", 
                    "country": "France", 
                    "zip": "78300"
                }, 
                "name": "Poissy Saint Germain en Laye Hospital"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Levobupivacaine Continuous Wound Infiltration and Optimal Standard Analgesia Versus Optimal Standard Analgesia Alone After Cesarean Section.", 
        "overall_official": {
            "affiliation": "Poissy-Saint Germain Hospital", 
            "last_name": "Claude JOLLY, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Quantity of morphine injected by the patient controlled analgesia pump", 
            "measure": "Postoperative morphine consumption", 
            "safety_issue": "No", 
            "time_frame": "24 first hours after cesarean section"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01751256"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Poissy-Saint Germain Hospital", 
            "investigator_full_name": "Claude JOLLY", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Numerical pain scale during mobilization", 
                "measure": "Pain at mobilization", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16, 20, 24, 36, 48 and 78 hours after skin closure, entrance and exit from the recovery room"
            }, 
            {
                "description": "Time taken for early walking", 
                "measure": "Early walking", 
                "safety_issue": "No", 
                "time_frame": "in the 72 first hours after skin closure"
            }, 
            {
                "description": "Interval from the end of surgery until the first gas from the intestinal tract", 
                "measure": "Resumption of gastrointestinal function", 
                "safety_issue": "No", 
                "time_frame": "First 72 hours after skin closure"
            }, 
            {
                "description": "Nausea, vomiting, pruritus, excessive sedation", 
                "measure": "Treatment tolerance", 
                "safety_issue": "Yes", 
                "time_frame": "First 72 hours after skin closure"
            }, 
            {
                "description": "Analogic numerical scale on a specific form", 
                "measure": "Maternal satisfaction", 
                "safety_issue": "No", 
                "time_frame": "2 days after skin closure"
            }, 
            {
                "description": "Number of intervention for nursing, breastfeeding help, and cesarean wound dressing change", 
                "measure": "Health staff workload", 
                "safety_issue": "No", 
                "time_frame": "For the 48 first hours after skin closure"
            }, 
            {
                "description": "Number of wound infection needing specific cares appeared during the observation time", 
                "measure": "Wound infections", 
                "safety_issue": "Yes", 
                "time_frame": "the first 10 days after skin closure"
            }, 
            {
                "description": "Every adverse effect attributed to local anaesthetic by an skilled anesthesiologist", 
                "measure": "Local anaesthetic systemic toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "During the first 48 hours after skin closure"
            }, 
            {
                "description": "Discomfort caused by the material and pain at retrieval of the catheter, assessed by an analogic scale on a specific form", 
                "measure": "Discomfort due to material", 
                "safety_issue": "Yes", 
                "time_frame": "At catheter retrieval"
            }, 
            {
                "description": "Premature withdrawal or occlusion of the catheter", 
                "measure": "Technical problems related to the catheter", 
                "safety_issue": "Yes", 
                "time_frame": "During the 48 first hours after skin closure"
            }, 
            {
                "description": "Numerical pain scale at rest", 
                "measure": "Pain at rest", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16, 20, 24, 36, 48 and 78 hours after skin closure, entrance and exit from the recovery room"
            }, 
            {
                "description": "Analogic numerical scale on a specific form", 
                "measure": "Comfort with Breast Feeding", 
                "safety_issue": "No", 
                "time_frame": "For the the 48 first hours after skin closure"
            }, 
            {
                "description": "Postpartum hemorrhage or every adverse event occurred during the observation period.", 
                "measure": "All cause morbidity", 
                "safety_issue": "Yes", 
                "time_frame": "For the first 10 days after skin closure"
            }
        ], 
        "source": "Poissy-Saint Germain Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Poissy-Saint Germain Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}